285 related articles for article (PubMed ID: 29713603)
1. Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective.
Nakhlband A; Eskandani M; Omidi Y; Saeedi N; Ghaffari S; Barar J; Garjani A
Bioimpacts; 2018; 8(1):59-75. PubMed ID: 29713603
[No Abstract] [Full Text] [Related]
2. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
Alaarg A; Senders ML; Varela-Moreira A; Pérez-Medina C; Zhao Y; Tang J; Fay F; Reiner T; Fayad ZA; Hennink WE; Metselaar JM; Mulder WJM; Storm G
J Control Release; 2017 Sep; 262():47-57. PubMed ID: 28700897
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities.
Mittal R; Jhaveri VM; Kay SS; Greer A; Sutherland KJ; McMurry HS; Lin N; Mittal J; Malhotra AK; Patel AP
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):19-32. PubMed ID: 29737266
[TBL] [Abstract][Full Text] [Related]
4. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis.
Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J
Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000
[TBL] [Abstract][Full Text] [Related]
5. Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis.
Liu H; Pietersz G; Peter K; Wang X
J Nanobiotechnology; 2022 Feb; 20(1):75. PubMed ID: 35135581
[TBL] [Abstract][Full Text] [Related]
6. Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis.
Gaurav C; Saurav B; Goutam R; Goyal AK
Curr Pharm Des; 2015; 21(30):4498-508. PubMed ID: 26377651
[TBL] [Abstract][Full Text] [Related]
7. Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy.
Xu X; Li T; Jin K
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631695
[TBL] [Abstract][Full Text] [Related]
8. Combination antitumor therapy with targeted dual-nanomedicines.
Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
[TBL] [Abstract][Full Text] [Related]
9. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates.
Akbarzadeh Khiavi M; Safary A; Somi MH
Bioimpacts; 2019; 9(3):123-127. PubMed ID: 31508327
[TBL] [Abstract][Full Text] [Related]
11. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
[TBL] [Abstract][Full Text] [Related]
12. Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives.
Manners N; Priya V; Mehata AK; Rawat M; Mohan S; Makeen HA; Albratty M; Albarrati A; Meraya AM; Muthu MS
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455438
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles: a promising therapeutic approach in atherosclerosis.
Antoniades C; Psarros C; Tousoulis D; Bakogiannis C; Shirodaria C; Stefanadis C
Curr Drug Deliv; 2010 Oct; 7(4):303-11. PubMed ID: 20695841
[TBL] [Abstract][Full Text] [Related]
14. Novel cutting edge nano-strategies to address old long-standing complications in cardiovascular diseases. A comprehensive review.
Tesoro L; Hernandez I; Saura M; Badimón L; Zaragoza C
Eur J Clin Invest; 2024 Jul; 54(7):e14208. PubMed ID: 38622800
[TBL] [Abstract][Full Text] [Related]
15. Nanomaterials as Novel Cardiovascular Theranostics.
Pala R; Pattnaik S; Busi S; Nauli SM
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33799932
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.
Singh AP; Biswas A; Shukla A; Maiti P
Signal Transduct Target Ther; 2019; 4():33. PubMed ID: 31637012
[TBL] [Abstract][Full Text] [Related]
17. Biomimetic nanomedicines for precise atherosclerosis theranostics.
Tao Y; Lan X; Zhang Y; Fu C; Liu L; Cao F; Guo W
Acta Pharm Sin B; 2023 Nov; 13(11):4442-4460. PubMed ID: 37969739
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine for the prevention, treatment and imaging of atherosclerosis.
Psarros C; Lee R; Margaritis M; Antoniades C
Maturitas; 2012 Sep; 73(1):52-60. PubMed ID: 22261366
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Managing Atherosclerosis via Nanomedicine.
Chan CKW; Zhang L; Cheng CK; Yang H; Huang Y; Tian XY; Choi CHJ
Small; 2018 Jan; 14(4):. PubMed ID: 29239134
[TBL] [Abstract][Full Text] [Related]
20. A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque.
Anwaier G; Chen C; Cao Y; Qi R
Int J Nanomedicine; 2017; 12():7681-7693. PubMed ID: 29089763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
